Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
暂无分享,去创建一个
[1] K. Turksen,et al. Isolation and characterization , 2006 .
[2] G. Engelhardt,et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance , 1995, Inflammation Research.
[3] P. Barnes,et al. Modulation of bradykinin responses in airway smooth muscle by epithelial enzymes , 1990, Agents and Actions.
[4] D. Willoughby,et al. The effect of indomethacin on cartilage breakdown , 1989, Agents and Actions.
[5] P. Platt. Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee , 1989, Clinical Rheumatology.
[6] J. Arnold,et al. Etodolac, a new nonsteroidal anti-inflammatory drug: Gastrointestinal microbleeding and endoscopic studies , 1989, Clinical Rheumatology.
[7] D. P. Carr,et al. Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the rat , 1986, Agents and Actions.
[8] S. Holgate. The pathophysiology of bronchial asthma and targets for its drug treatment , 1986, Agents and Actions.
[9] S. Konturek,et al. Comparison of prostacyclin and prostaglandin E2 on gastric secretion, gastrin release, and mucosal blood flow in dogs , 1980, Digestive Diseases and Sciences.
[10] U. Euler. Über die Spezifische Blutdrucksenkende Substanz des Menschlichen Prostata- und Samenblasensekretes , 1935, Klinische Wochenschrift.
[11] D. Nompleggi,et al. A comparison of the effects of prostacyclin and the 15 (S), 15-methyl analogs of PGE2 and PGF2α on gastric parietal and nonparietal secretion , 2005, Digestive Diseases and Sciences.
[12] A. Brash,et al. On the Evolutionary Origin of Cyclooxygenase (COX) Isozymes , 2004, Journal of Biological Chemistry.
[13] F. Porzio. Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee , 2004, Rheumatology International.
[14] R. Ramer,et al. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. , 2003, Molecular pharmacology.
[15] Li Zhu,et al. Methanandamide increases COX‐2 expression and tumor growth in murine lung cancer , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] K. Chadee,et al. Identification and characterization of a cyclooxygenase-like enzyme from Entamoeba histolytica , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] T. Iwama,et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] M. Taketo,et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. , 2003, Cancer research.
[19] J. Wolford,et al. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians , 2003, Human Genetics.
[20] C. Saper,et al. Specific roles of cyclooxygenase‐1 and cyclooxygenase‐2 in lipopolysaccharide‐induced fever and fos expression in rat brain , 2003, The Journal of comparative neurology.
[21] J. Little,et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. , 2003, Gastroenterology.
[22] R. Hunt,et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events , 2003, American Journal of Gastroenterology.
[23] J. Kleibeuker,et al. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas , 2003, The Lancet.
[24] T. Hla,et al. The RNA-binding Protein HuR Regulates the Expression of Cyclooxygenase-2* , 2003, Journal of Biological Chemistry.
[25] Howard S. Smith,et al. Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population , 2003, The American journal of hospice & palliative care.
[26] L. Marnett,et al. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. , 2003, Biochemistry.
[27] D. Simmons. Variants of cyclooxygenase-1 and their roles in medicine. , 2003, Thrombosis research.
[28] D. Dixon. Regulation of COX-2 expression in human cancers. , 2003, Progress in experimental tumor research.
[29] J. Pfeilschifter,et al. Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. , 2003, The Journal of investigative dermatology.
[30] O. Boutaud,et al. Tristetraprolin Binds to the 3′-Untranslated Region of Cyclooxygenase-2 mRNA , 2003, The Journal of Biological Chemistry.
[31] A. Nicolini,et al. Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase , 2003, Journal of neuroscience research.
[32] G. Beck,et al. A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.
[33] Susan Halabi,et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.
[34] J. Trzăskos,et al. COX-3: in the wrong frame in mind. , 2003, Immunology letters.
[35] E. Ricciotti,et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells , 2003, British journal of pharmacology.
[36] D. Aronoff,et al. Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes. , 2003, Advances in experimental medicine and biology.
[37] K. Claffey,et al. Leptomycin B, an Inhibitor of the Nuclear Export Receptor CRM1, Inhibits COX-2 Expression* , 2003, The Journal of Biological Chemistry.
[38] M. Halushka,et al. Genetic variation in cyclooxygenase 1: Effects on response to aspirin , 2003, Clinical pharmacology and therapeutics.
[39] F. Marks,et al. Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[40] P. Reddanna,et al. Expression of cyclooxygenase-2 in rat testis. , 2003, Reproductive biomedicine online.
[41] 塩川左斗志. COX-1/COX-2 , 2003 .
[42] J. Baron. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. , 2003, Progress in experimental tumor research.
[43] J. Morrow,et al. Metabolism of the Endocannabinoids, 2-Arachidonylglycerol and Anandamide, into Prostaglandin, Thromboxane, and Prostacyclin Glycerol Esters and Ethanolamides* , 2002, The Journal of Biological Chemistry.
[44] Henry J. Lin,et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[45] Jeannette Bigler,et al. Cyclooxygenase 1 (COX1) polymorphisms in African‐American and caucasian populations , 2002, Human mutation.
[46] N. Bresolin,et al. A collection of 33 novel human mtDNA homoplasmic variants , 2002, Human mutation.
[47] A. Carvajal,et al. Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System. , 2002, Clinical pharmacology and therapeutics.
[48] Y. Bezugla,et al. Diverse functional coupling of cyclooxygenase 1 and 2 with final prostanoid synthases in liver macrophages. , 2002, Biochemical pharmacology.
[49] S. Humphries,et al. Common Promoter Variant in Cyclooxygenase-2 Represses Gene Expression: Evidence of Role in Acute-Phase Inflammatory Response , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[50] C. Patrono,et al. Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury? , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[51] N. V. Chandrasekharan,et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[52] S. Laulederkind,et al. Renal pathology resulting from PGHS-2 gene ablation in DBA/B6 mice. , 2002, Prostaglandins & other lipid mediators.
[53] Makoto Murakami,et al. Prostaglandin E synthase. , 2002, Prostaglandins & other lipid mediators.
[54] D. Morgan,et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. , 2002, The American journal of pathology.
[55] M. Malkowski,et al. The structures of prostaglandin endoperoxide H synthases-1 and -2. , 2002, Prostaglandins & other lipid mediators.
[56] B. Levin,et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis , 2002, Gut.
[57] Lawrence J. Marnett,et al. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[58] N. Shibata,et al. 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. , 2002, The Journal of biological chemistry.
[59] Juan J Perez,et al. Differential binding mode of diverse cyclooxygenase inhibitors. , 2002, Journal of molecular graphics & modelling.
[60] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[61] S. Powell,et al. Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. , 2002, Nucleic acids research.
[62] M. Zemel,et al. Prostaglandin E2 Protects Intestinal Tumors from Nonsteroidal Anti-inflammatory Drug-induced Regression in ApcMin/+ Mice , 2002 .
[63] L. Marnett,et al. Control of Prostaglandin Stereochemistry at the 15-Carbon by Cyclooxygenases-1 and -2 , 2002, The Journal of Biological Chemistry.
[64] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors☆ , 2002 .
[65] M. Zemel,et al. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. , 2002, Cancer research.
[66] M. Murakami,et al. Functional coupling between phospholipase A2S and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. , 2002, Advances in experimental medicine and biology.
[67] Changhai Ding,et al. Lumiracoxib (Novartis). , 2002, IDrugs : the investigational drugs journal.
[68] D. Bell,et al. Functional characterization of cyclooxygenase-2 polymorphisms. , 2001, The Journal of pharmacology and experimental therapeutics.
[69] William L. Smith,et al. Structure of Eicosapentaenoic and Linoleic Acids in the Cyclooxygenase Site of Prostaglandin Endoperoxide H Synthase-1* , 2001, The Journal of Biological Chemistry.
[70] S. Shyue,et al. Colocalization and Interaction of Cyclooxygenase-2 with Caveolin-1 in Human Fibroblasts* , 2001, The Journal of Biological Chemistry.
[71] M. Murakami,et al. Coupling between Cyclooxygenase, Terminal Prostanoid Synthase, and Phospholipase A2 * , 2001, The Journal of Biological Chemistry.
[72] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[73] G. Pasinetti,et al. Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. , 2001, Archives of gerontology and geriatrics.
[74] A. Grothey,et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? , 2001, Journal of Cancer Research and Clinical Oncology.
[75] A. Brash,et al. The origin of 15R-prostaglandins in the Caribbean coral Plexaura homomalla: Molecular cloning and expression of a novel cyclooxygenase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[76] P. Weller,et al. Extranuclear Lipid Bodies, Elicited by CCR3-mediated Signaling Pathways, Are the Sites of Chemokine-enhanced Leukotriene C4 Production in Eosinophils and Basophils* , 2001, The Journal of Biological Chemistry.
[77] Aubrey R. Morrison,et al. The 3′-Untranslated Region of Murine Cyclooxygenase-2 Contains Multiple Regulatory Elements That Alter Message Stability and Translational Efficiency* , 2001, The Journal of Biological Chemistry.
[78] P. O’Brien,et al. Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels. , 2001, Carcinogenesis.
[79] K. Subbaramaiah,et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. , 2001, Endocrine-related cancer.
[80] F. Marks,et al. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[81] T. Hla,et al. Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.
[82] M. Kay Washington,et al. Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma Cells* , 2001, The Journal of Biological Chemistry.
[83] L. Favalli,et al. The Cycloxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat , 2001, Neuroscience Letters.
[84] P. Loll,et al. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. , 2001, Biochemistry.
[85] M. Respondek,et al. Effects of specific inhibition of cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 in the rat stomach with normal mucosa and after acid challenge , 2001, British journal of pharmacology.
[86] W. Ettinger,et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis , 2001, Aging.
[87] P. Bozza,et al. Arachidonyl trifluoromethyl ketone induces lipid body formation in leukocytes. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.
[88] William L. Smith,et al. Prostaglandin Endoperoxide H Synthase-1 , 2001, The Journal of Biological Chemistry.
[89] A. Blomqvist,et al. Inflammatory response: Pathway across the blood–brain barrier , 2001, Nature.
[90] E. Moses,et al. Asexual reproduction: 'Midwives' assist dividing amoebae , 2001, Nature.
[91] Adam Sapirstein,et al. Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity , 2001, Nature.
[92] M. Percival,et al. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. , 2001, Archives of biochemistry and biophysics.
[93] B. Thjódleifsson,et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen , 2001, Gut.
[94] M. Hori,et al. Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. , 2001, Journal of experimental & clinical cancer research : CR.
[95] J. Buxbaum,et al. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. , 2001, Archives of neurology.
[96] A. Kalgutkar,et al. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. , 2001, Current drug targets.
[97] Bert Vogelstein,et al. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[98] R. Caprioli,et al. Characterization of the glycosylation sites in cyclooxygenase-2 using mass spectrometry. , 2001, Biochemistry.
[99] R Gordon,et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. , 2001, The Journal of pharmacology and experimental therapeutics.
[100] G. Rosoklija,et al. Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis , 2001, Annals of neurology.
[101] J. Gimbel,et al. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. , 2001, Clinical therapeutics.
[102] W. Kiefer,et al. Cyclooxygenase inhibitors--current status and future prospects. , 2001, European journal of medicinal chemistry.
[103] E. Oliw,et al. The selective cyclooxygenase‐2 inhibitor rofecoxib reduces kainate‐induced cell death in the rat hippocampus , 2001, The European journal of neuroscience.
[104] H. S. Kim,et al. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. , 2001, The Journal of clinical investigation.
[105] James A. Clark,et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[106] M. Ross,et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[107] J. Marx. Anti-Inflammatories Inhibit Cancer Growth--But How? , 2001, Science.
[108] M. Malkowski,et al. Prostaglandin Endoperoxide H Synthase-1 THE FUNCTIONS OF CYCLOOXYGENASE ACTIVE SITE RESIDUES IN THE BINDING, POSITIONING, AND OXYGENATION OF ARACHIDONIC ACID* h S , 2001 .
[109] J. Vane,et al. Therapeutic Roles Of Selective Cox-2 Inhibitors , 2001 .
[110] A. Thomson. NSAID-Induced Gastric Damage in Rats , 2001 .
[111] P. Aisen,et al. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. , 2001, Clinical and experimental rheumatology.
[112] J. Marx. Cancer research. Anti-inflammatories inhibit cancer growth--but how? , 2001, Science.
[113] S A Rich,et al. The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.
[114] K. Kinzler,et al. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[115] D. Krupa,et al. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. , 2001, American journal of orthopedics.
[116] H. Farber,et al. Induction of endothelial cell cytoplasmic lipid bodies during hypoxia. , 2001, American journal of physiology. Heart and circulatory physiology.
[117] L. Marnett,et al. Catalytic Consumption of Nitric Oxide by Prostaglandin H Synthase-1 Regulates Platelet Function* , 2000, The Journal of Biological Chemistry.
[118] K. Matsui,et al. Molecular characterization of fatty acid α-hydroperoxide-forming enzyme (α-oxygenase) in rice plants , 2000 .
[119] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[120] M. Foschi,et al. Cyclooxygenase 2 Promotes Cell Survival by Stimulation of Dynein Light Chain Expression and Inhibition of Neuronal Nitric Oxide Synthase Activity , 2000, Molecular and Cellular Biology.
[121] D. M. van der Heijde,et al. Rofecoxib, a New Cyclooxygenase 2 Inhibitor, Shows Sustained Efficacy, Comparable With Other Nonsteroidal Anti-inflammatory Drugs A 6-Week and a 1-Year Trial in Patients With Osteoarthritis , 2000 .
[122] L. Waite,et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. , 2000, Archives of neurology.
[123] Moore Bc,et al. COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. , 2000 .
[124] L. Crofford. Clinical experience with specific COX-2 inhibitors in arthritis. , 2000, Current pharmaceutical design.
[125] J. Bolognese,et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin , 2000, Gut.
[126] M. Hüll,et al. Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E2 synthesis in rat microglial cells , 2000, Neuropharmacology.
[127] M. Breyer,et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. , 2000, Kidney international.
[128] A. Bennett. The importance of COX-2 inhibition for aspirin induced asthma , 2000, Thorax.
[129] Y. Sugimoto,et al. Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. , 2000, Japanese journal of pharmacology.
[130] M. Malkowski,et al. The productive conformation of arachidonic acid bound to prostaglandin synthase. , 2000, Science.
[131] K. Seibert,et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.
[132] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[133] J. Wallace,et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. , 2000, Gastroenterology.
[134] R. Langenbach,et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. , 2000, Cancer research.
[135] J. Vane,et al. Nociception in cyclooxygenase isozyme-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[136] R. Hunt,et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. , 2000, The American journal of medicine.
[137] K. Ashe,et al. Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.
[138] Kaiming Xu,et al. Immediate-early MEK-1-dependent Stabilization of Rat Smooth Muscle Cell Cyclooxygenase-2 mRNA by Gαq-coupled Receptor Signaling* , 2000, The Journal of Biological Chemistry.
[139] S. Swan,et al. Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet , 2000, Annals of Internal Medicine.
[140] R. Mann,et al. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. , 2000, British journal of clinical pharmacology.
[141] F. Silverstein,et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor , 2000, American Journal of Gastroenterology.
[142] J. Bolognese,et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. , 2000, Archives of internal medicine.
[143] Gary Brewer,et al. Regulation of Cyclooxygenase 2 mRNA Stability by the Mitogen-Activated Protein Kinase p38 Signaling Cascade , 2000, Molecular and Cellular Biology.
[144] S. Dey,et al. Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.
[145] L. Marnett,et al. Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. , 2000, Biochemistry.
[146] S. Shyue,et al. Colocalization of Prostacyclin Synthase with Prostaglandin H Synthase-1 (PGHS-1) but Not Phorbol Ester-induced PGHS-2 in Cultured Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[147] J. Bolognese,et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. , 2000, Arthritis and rheumatism.
[148] W. Maddrey,et al. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. , 2000, American journal of therapeutics.
[149] P. O’Brien,et al. Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[150] C. Glass,et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[151] K. Seibert,et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.
[152] L. Marnett,et al. Substitution of tyrosine for the proximal histidine ligand to the heme of prostaglandin endoperoxide synthase 2: implications for the mechanism of cyclooxygenase activation and catalysis. , 2000, Biochemistry.
[153] Gary W. Williams,et al. Treatment of Osteoarthritis with a Once‐Daily Dosing Regimen of Celecoxib: A Randomized, Controlled Trial , 2000, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[154] H. Zeidler,et al. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. , 2000, Clinical therapeutics.
[155] P. Pizcueta,et al. Circulating concentrations of soluble L-selectin (CD62L) in patients with primary Sjögren's syndrome , 2000, Annals of the rheumatic diseases.
[156] S. Narumiya,et al. Prostaglandin D2 as a mediator of allergic asthma. , 2000, Science.
[157] L. Marnett,et al. Spatial Requirements for 15-(R)-Hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic Acid Synthesis within the Cyclooxygenase Active Site of Murine COX-2 , 2000, The Journal of Biological Chemistry.
[158] S. Lanes,et al. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin , 2000, Pharmacoepidemiology and drug safety.
[159] R. S. Rogers,et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. , 2000, Journal of medicinal chemistry.
[160] R. Sartor,et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. , 2000, The Journal of clinical investigation.
[161] P. Isakson,et al. Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial , 2000, Journal of clinical pharmacology.
[162] M. Kondo,et al. 15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats , 2000 .
[163] G. Natoli,et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.
[164] H. Budka,et al. Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans , 2000, Acta Neuropathologica.
[165] Claire Shepherd,et al. Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms , 2000, Clinical and experimental pharmacology & physiology.
[166] D. Straus. 15-deoxy Δ^ -PGJ2 inhibits multiple steps in the NF-kappaB signaling pathway , 2000 .
[167] Aldons J. Lusis,et al. Atherosclerosis : Vascular biology , 2000 .
[168] M. Kondo,et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. , 2000, The Journal of clinical investigation.
[169] R. Garavito,et al. Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.
[170] L. Marnett. Cyclooxygenase mechanisms. , 2000, Current opinion in chemical biology.
[171] R. Veerhuis,et al. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain , 2000, Acta Neuropathologica.
[172] D. Simmons,et al. COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. , 2000, Current medicinal chemistry.
[173] P. Isakson,et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison , 1999, The Lancet.
[174] O. Laneuville,et al. Characterization of a novel transcript of prostaglandin endoperoxide H synthase 1 with a tissue-specific profile of expression. , 1999, The Biochemical journal.
[175] P. Schoenfeld. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. , 1999, The American journal of medicine.
[176] T. Hla,et al. Overexpression of Cyclooxygenase-2 Induces Cell Cycle Arrest , 1999, The Journal of Biological Chemistry.
[177] D. Graham,et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. , 1999, JAMA.
[178] J. Bolognese,et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. , 1999, JAMA.
[179] R. Garavito,et al. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. , 1999, Biochimica et biophysica acta.
[180] E. Tindall. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. , 1999, The Journal of the American Osteopathic Association.
[181] T. Schnitzer,et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. , 1999, The Journal of rheumatology.
[182] P. Isakson,et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.
[183] S. Narumiya,et al. Impaired duodenal bicarbonate secretion and mucosal integrity in mice lacking prostaglandin E-receptor subtype EP(3). , 1999, Gastroenterology.
[184] K. Kinzler,et al. PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.
[185] Morgan Rw. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999 .
[186] E. Baik,et al. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus , 1999, Brain Research.
[187] L. Laine,et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. , 1999, Gastroenterology.
[188] B. Verbruggen,et al. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers , 1999, Clinical pharmacology and therapeutics.
[189] R. Langenbach,et al. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. , 1999, Biochemical pharmacology.
[190] R. Langenbach,et al. Cyclooxygenase‐deficient Mice: A Summary of Their Characteristics and Susceptibilities to Inflammation and Carcinogenesis , 1999, Annals of the New York Academy of Sciences.
[191] O'Banion,et al. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. , 1999, Expert opinion on investigational drugs.
[192] A. Osbourn,et al. Cloning of Linoleate Diol Synthase Reveals Homology with Prostaglandin H Synthases* , 1999, The Journal of Biological Chemistry.
[193] S. Daniels,et al. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. , 1999, Clinical therapeutics.
[194] T. Schnitzer,et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. , 1999, Clinical therapeutics.
[195] S. Daniels,et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. , 1999, Obstetrics and gynecology.
[196] P. Libby,et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.
[197] G. Pasinetti,et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. , 1999, The American journal of pathology.
[198] J. Mcgiff,et al. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. , 1999, American journal of physiology. Renal physiology.
[199] S. Narumiya,et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[200] M. Hamberg,et al. α-Oxidation of Fatty Acids in Higher Plants , 1999, The Journal of Biological Chemistry.
[201] M. Hamberg,et al. alpha-oxidation of fatty acids in higher plants. Identification of a pathogen-inducible oxygenase (piox) as an alpha-dioxygenase and biosynthesis of 2-hydroperoxylinolenic acid. , 1999, The Journal of biological chemistry.
[202] R. Langenbach,et al. Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (Nsaids) on Cyclooxygenase-Null Embryo Fibroblasts , 1999, The Journal of experimental medicine.
[203] H Perrier,et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.
[204] R. Kulmacz,et al. Hydroperoxide Dependence and Cooperative Cyclooxygenase Kinetics in Prostaglandin H Synthase-1 and -2* , 1999, The Journal of Biological Chemistry.
[205] M. Percival,et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.
[206] C. Patrono,et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. , 1999, The Journal of pharmacology and experimental therapeutics.
[207] Šimon Scharf,et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.
[208] J. Vane,et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[209] A. Mulichak,et al. The Role of Arginine 120 of Human Prostaglandin Endoperoxide H Synthase-2 in the Interaction with Fatty Acid Substrates and Inhibitors* , 1999, The Journal of Biological Chemistry.
[210] T. Hla,et al. Endothelial Cell Apoptosis Induced by the Peroxisome Proliferator-activated Receptor (PPAR) Ligand 15-Deoxy-Δ12,14-prostaglandin J2 * , 1999, The Journal of Biological Chemistry.
[211] P. Mcgeer,et al. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs , 1999, Brain Research.
[212] W. Wetsel,et al. Anovulation in Cyclooxygenase-2-Deficient Mice Is Restored by Prostaglandin E2 and Interleukin-1β. , 1999, Endocrinology.
[213] W. Yuan,et al. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. , 1999, Clinical therapeutics.
[214] D. Badesch,et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[215] H. S. Kim,et al. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. , 1999, The Journal of clinical investigation.
[216] J. Bolognese,et al. Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen , 1999, Alimentary pharmacology & therapeutics.
[217] K. Grasing,et al. Cyclooxygenase‐2 inhibition by rofecoxib reverses naturally occurring fever in humans , 1999, Clinical pharmacology and therapeutics.
[218] D. Gilroy,et al. Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.
[219] N. Voelkel,et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.
[220] J. Lefkowith. Cyclooxygenase-2 specificity and its clinical implications. , 1999, The American journal of medicine.
[221] G. FitzGerald,et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.
[222] J. Lötsch,et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state , 1999, Clinical pharmacology and therapeutics.
[223] E. Huskisson,et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: An active controlled equivalence study , 1999 .
[224] K. Rainsford. Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. , 1999, Rheumatology.
[225] D. Fitzgerald,et al. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. , 1999, Rheumatology.
[226] J. Gierse,et al. Kinetic basis for selective inhibition of cyclo-oxygenases. , 1999, The Biochemical journal.
[227] Y. Wang,et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2−/−, but not in cyclooxygenase-1−/− mice , 1999, Brain Research.
[228] G. Triadafilopoulos,et al. Epidemiology of NSAID induced gastrointestinal complications. , 1999, The Journal of rheumatology. Supplement.
[229] J. Vance,et al. Mechanisms of lipid-body formation. , 1999, Trends in biochemical sciences.
[230] C. Berr. [Epidemiology of Alzheimer's disease]. , 1999, Servir.
[231] C. Bayly,et al. Structure-based design of COX-2 selectivity into flurbiprofen. , 1999, Bioorganic & medicinal chemistry letters.
[232] Mark A. Magnuson,et al. Salt–sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor , 1999, Nature Medicine.
[233] P. Gebicke-haerter,et al. Increased Expression of Cyclooxygenases and Peroxisome Proliferator-Activated Receptor-γ in Alzheimer's Disease Brains , 1999 .
[234] W. Ray,et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. , 1999, Archives of internal medicine.
[235] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[236] Carreira,et al. Cyclooxygenase‐1 and ‐2 are expressed by human T cells , 1999, Clinical and experimental immunology.
[237] S. D. Moore,et al. Expression of prostaglandin H synthase isoforms in human myometrium at parturition. , 1999, American journal of obstetrics and gynecology.
[238] H. Herschman,et al. Function and regulation of prostaglandin synthase 2. , 1999, Advances in experimental medicine and biology.
[239] S. Ritland,et al. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. , 1999, Carcinogenesis.
[240] A. Giulio,et al. Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity. , 1998, The Journal of pharmacy and pharmacology.
[241] P. Mannon,et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. , 1998, The Journal of clinical investigation.
[242] J. Dean,et al. A p38 MAP kinase inhibitor regulates stability of interleukin‐1‐induced cyclooxygenase‐2 mRNA , 1998, FEBS letters.
[243] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.
[244] M. Taketo. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.
[245] D. Fitzgerald,et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. , 1998, The Journal of pharmacology and experimental therapeutics.
[246] C. Koboldt,et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[247] A. Bernareggi. Clinical Pharmacokinetics of Nimesulide , 1998, Clinical pharmacokinetics.
[248] Atsushi Ichikawa,et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 , 1998, Nature.
[249] C. Hawkey,et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. , 1998, British journal of rheumatology.
[250] C. Hawkey,et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. , 1998, British journal of rheumatology.
[251] A. Macciocchi,et al. GASTRODUODENAL TOLERABILITY OF NIMESULIDE AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS , 1998 .
[252] T. Warner,et al. Interactions between inducible isoforms of nitric oxide synthase and cyclo‐oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib , 1998, British journal of pharmacology.
[253] A. Sanz,et al. PIOX, a New Pathogen-Induced Oxygenase with Homology to Animal Cyclooxygenase , 1998, Plant Cell.
[254] E. Oliw,et al. Analysis of novel hydroperoxides and other metabolites of oleic, linoleic, and linolenic acids by liquid chromatography-mass spectrometry with ion trap MSn , 1998, Lipids.
[255] W. Seeger,et al. Vasoregulatory prostanoid generation proceeds via cyclooxygenase-2 in noninflamed rat lungs. , 1998, The Journal of pharmacology and experimental therapeutics.
[256] P. Lipsky,et al. Cyclooxygenase in biology and disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[257] M. Sahlin,et al. A Protein Radical and Ferryl Intermediates Are Generated by Linoleate Diol Synthase, a Ferric Hemeprotein with Dioxygenase and Hydroperoxide Isomerase Activities* , 1998, The Journal of Biological Chemistry.
[258] N. Delanty,et al. Risk of Alzheimer's disease and duration of NSAID use , 1998, Neurology.
[259] G. Singh,et al. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. , 1998, The American journal of medicine.
[260] R. DuBois,et al. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.
[261] A. Walker,et al. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy , 1998, European Journal of Clinical Pharmacology.
[262] A. R. Santos,et al. Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in mice , 1998, Inflammation Research.
[263] K. Bley,et al. Characterization of prostanoid receptor‐evoked responses in rat sensory neurones , 1998, British journal of pharmacology.
[264] C. Patrono,et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings , 1998, Clinical pharmacology and therapeutics.
[265] J. van Ryn,et al. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer , 1998, Inflammation Research.
[266] S. Narumiya,et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. , 1998, Biochemical and biophysical research communications.
[267] K. Yamagata,et al. Cyclooxygenase-2 is induced in brain blood vessels during fever evoked by peripheral or central administration of tumor necrosis factor. , 1998, Brain research. Molecular brain research.
[268] D. Busija,et al. In vitro and in vivo localization of prostaglandin H synthase in fetal sheep neurons , 1998, Neuroscience Letters.
[269] S. Rabe-Hesketh,et al. Do anti‐arthritic drugs decrease the risk for cognitive decline? , 1998, Neurology.
[270] S. Rabe-Hesketh,et al. Do antiarthritic drugs decrease the risk for cognitive decline? An analysis based on data from the MRC treatment trial of hypertension in older adults. , 1998, Neurology.
[271] K. Seibert,et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.
[272] C. H. Liu,et al. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3'-untranslated region. , 1998, Biochemical and biophysical research communications.
[273] L. G. García Rodríguez,et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. , 1998, Archives of internal medicine.
[274] R. Gryglewski. Aspirin-induced asthma and cyclooxygenases , 1998 .
[275] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. , 1998, Nature.
[276] M. Taketo. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). , 1998, Journal of the National Cancer Institute.
[277] E. Bluhmki,et al. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. , 1998, Scandinavian journal of rheumatology.
[278] L. Marnett,et al. Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. , 1998, Current opinion in chemical biology.
[279] R. Stahl,et al. Cyclooxygenase-2 (COX-2) and the kidney: current status and potential perspectives. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[280] C. Patrono,et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1997, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[281] K. Seibert,et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. , 1997, The Journal of pharmacology and experimental therapeutics.
[282] B. Koller,et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth , 1997, Nature.
[283] C. Bayly,et al. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. , 1997, Molecular pharmacology.
[284] S. Dey,et al. Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient Mice , 1997, Cell.
[285] M. Mcentee,et al. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. , 1997, Cancer research.
[286] A. Dvorak,et al. Eosinophil Lipid Bodies: Specific, Inducible Intracellular Sites for Enhanced Eicosanoid Formation , 1997, The Journal of experimental medicine.
[287] A. Korten,et al. Aspirin, anti‐inflammatory drugs and risk of dementia , 1997, International journal of geriatric psychiatry.
[288] A. Ristimäki,et al. Tumorigenic Transformation of Immortalized ECV Endothelial Cells by Cyclooxygenase-1 Overexpression* , 1997, The Journal of Biological Chemistry.
[289] S. Narumiya,et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.
[290] I. Adcock,et al. Evidence for Involvement of NF-κB in the Transcriptional Control of COX-2 Gene Expression by IL-1β ☆ , 1997 .
[291] S. Narumiya,et al. Failure of parturition in mice lacking the prostaglandin F receptor. , 1997, Science.
[292] C. Leffler,et al. Upregulation of COX-2 in cerebral microvascular endothelial cells by smooth muscle cell signals. , 1997, The American journal of physiology.
[293] E. Bluhmki,et al. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. , 1997, Osteoarthritis and cartilage.
[294] D. Salvemini. Regulation of cyclooxygenase enzymes by nitric oxide , 1997, Cellular and Molecular Life Sciences CMLS.
[295] S. Budsberg,et al. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. , 1997, American journal of veterinary research.
[296] F. Cerveró,et al. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: Central and peripheral components , 1997, Inflammation Research.
[297] P. Barnes,et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. , 1997, Molecular pharmacology.
[298] D. Swinney,et al. Differential Allosteric Regulation of Prostaglandin H Synthase 1 and 2 by Arachidonic Acid* , 1997, The Journal of Biological Chemistry.
[299] R. S. Rogers,et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.
[300] E. Bluhmki,et al. Efficacy and Tolerability of Meloxicam versus Piroxicam in Patients with Osteoarthritis of the Hip or Knee , 1997 .
[301] P. Aisen,et al. Maturational Regulation and Regional Induction of Cyclooxygenase-2 in Rat Brain: Implications for Alzheimer's Disease , 1997, Experimental Neurology.
[302] S. Takashima,et al. Induction of cyclo‐oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons , 1997, Neuroreport.
[303] V. László,et al. Histidine decarboxylase and intracellular histamine in melanoma cells and in a T cell line , 1997, Inflammation Research.
[304] J. Frölich,et al. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[305] R. Kurumbail,et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1997, Nature.
[306] Neustadt Dh. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. , 1997 .
[307] T. Schnitzer,et al. Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. , 1997, The Journal of rheumatology. Supplement.
[308] E. Bluhmki,et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. , 1997, The Journal of rheumatology.
[309] M. Yacoub,et al. Induction of cyclo‐oxygenase‐2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type , 1997, British journal of pharmacology.
[310] R. Lightfoot. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. , 1997, The Journal of rheumatology. Supplement.
[311] C. J. McCarthy,et al. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. , 1997, Arthritis and rheumatism.
[312] D. Riendeau,et al. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells , 1997, Inflammation Research.
[313] J. Morrow,et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[314] L. Liotta. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery , 1997 .
[315] D. Neustadt. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. , 1997, The Journal of rheumatology. Supplement.
[316] S. Yamamoto,et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. , 1997, Japanese journal of pharmacology.
[317] I. Adcock,et al. Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis. , 1996, Thorax.
[318] Y. Horie,et al. Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.
[319] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[320] J. Chow,et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.
[321] N. Bazan,et al. Sustained Induction of Prostaglandin Endoperoxide Synthase-2 by Seizures in Hippocampus , 1996, The Journal of Biological Chemistry.
[322] P. Bozza,et al. Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[323] W. Smith,et al. C-terminal Ser/Pro-Thr-Glu-Leu tetrapeptides of prostaglandin endoperoxide H synthases-1 and -2 target the enzymes to the endoplasmic reticulum. , 1996, Archives of Biochemistry and Biophysics.
[324] M. Gimbrone,et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[325] Yasuyoshi Watanabe,et al. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: a possible site of prostaglandin synthesis responsible for fever , 1996, Brain Research.
[326] S. Bevan,et al. PGE2 modulates the tetrodotoxin‐resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP‐protein kinase A cascade. , 1996, The Journal of physiology.
[327] W. Gibb,et al. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. , 1996, The Journal of endocrinology.
[328] K. Seibert,et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo , 1996, The Journal of experimental medicine.
[329] A. Ristimäki,et al. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. , 1996, The Biochemical journal.
[330] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[331] H T Hatoum,et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. , 1996, Archives of internal medicine.
[332] M. Goppelt‐Struebe,et al. Up‐regulation of cyclooxygenase‐2 mRNA in the rat spinal cord following peripheral inflammation , 1996, FEBS letters.
[333] R. Harris. The macula densa: recent developments. , 1996, Journal of hypertension.
[334] P. Loll,et al. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. , 1996, Biochemistry.
[335] B. A. Ballif,et al. Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[336] E. Huskisson,et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. , 1996, British journal of rheumatology.
[337] E. Bluhmki,et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. , 1996, British journal of rheumatology.
[338] E. Bluhmki,et al. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. , 1996, British journal of rheumatology.
[339] E. Bluhmki,et al. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. , 1996, British journal of rheumatology.
[340] G. Engelhardt. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. , 1996, British journal of rheumatology.
[341] C. Saper,et al. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide , 1996, Brain Research.
[342] P. Worley,et al. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[343] G. Passalacqua,et al. Nimesulide in the Treatment of Patients Intolerant of Aspirin and other NSAIDs , 1996, Drug safety.
[344] J. de Belleroche,et al. Cyclooxygenase‐2 Induction in Cerebral Cortex: An Intracellular Response to Synaptic Excitation , 1996, Journal of neurochemistry.
[345] R. Kurumbail,et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.
[346] T. Hla,et al. Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript. , 1996, Prostaglandins.
[347] M. Katori,et al. Cell types expressing COX-2 in rat carrageenin-induced pleurisy. , 1996 .
[348] P. Riel,et al. Development and Validation of Response Criteria in Rheumatoid Arthritis: Steps Towards an International Consensus on Prognostic Markers , 1996 .
[349] D. Dewitt,et al. Prostaglandin endoperoxide H synthases-1 and -2. , 1996, Advances in immunology.
[350] J. Falgueyret,et al. Arginine 120 of Prostaglandin G/H Synthase-1 Is Required for the Inhibition by Nonsteroidal Anti-inflammatory Drugs Containing a Carboxylic Acid Moiety * , 1995, The Journal of Biological Chemistry.
[351] S. Narumiya,et al. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs , 1995, British journal of pharmacology.
[352] B. Spiegelman,et al. 15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.
[353] J. Johnston,et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II , 1995, Nature.
[354] J. Mitchell,et al. Cyclooxygenase-2: regulation and relevance in inflammation. , 1995, Biochemical pharmacology.
[355] Hyung-Suk Kim,et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration , 1995, Cell.
[356] R. DuBois,et al. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.
[357] R. Langenbach,et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse , 1995, Cell.
[358] P. Isakson,et al. Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. , 1995, Journal of immunology.
[359] Yasuyoshi Watanabe,et al. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response , 1995, Brain Research.
[360] K. Ruan,et al. Topology of prostaglandin H synthase-1 in the endoplasmic reticulum membrane. , 1995, Archives of biochemistry and biophysics.
[361] G. Aldini,et al. Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. , 1995, Arzneimittel-Forschung.
[362] L. Crofford,et al. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin‐1: a potential mechanism for inflammatory angiogenesis , 1995, FEBS letters.
[363] P. Pasricha,et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. , 1995, Gastroenterology.
[364] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[365] William L. Smith,et al. Fatty Acid Substrate Specificities of Human Prostaglandin-endoperoxide H Synthase-1 and −2 , 1995, The Journal of Biological Chemistry.
[366] A. Hofman,et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? , 1995, Neurology.
[367] J. Regan,et al. Cloning of human prostanoid receptors. , 1995, Trends in pharmacological sciences.
[368] Daniel Picot,et al. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.
[369] M. Pericak-Vance,et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs , 1995, Neurobiology of Aging.
[370] M. Vasko,et al. Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3',5'-cyclic monophosphate transduction cascade , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[371] S Jothy,et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.
[372] J. Otto,et al. Different Intracellular Locations for Prostaglandin Endoperoxide H Synthase-1 and −2 (*) , 1995, The Journal of Biological Chemistry.
[373] D. Dewitt,et al. Characterization of inducible cyclooxygenase in rat brain , 1995, The Journal of comparative neurology.
[374] J. Vane,et al. Co‐induction of nitric oxide synthase and cyclo‐oxygenase: interactions between nitric oxide and prostanoids , 1995, British journal of pharmacology.
[375] H. Onoe,et al. Prostacyclin receptor in the brain and central terminals of the primary sensory neurons: An autoradiographic study using a stable prostacyclin analogue [3H]iloprost , 1995, Neuroscience.
[376] I. Pavord,et al. Bronchoprotective role for endogenous prostaglandin E2 , 1995, The Lancet.
[377] R. Kulmacz,et al. Prostaglandin H synthase-1: evaluation of C-terminus function. , 1995, Archives of biochemistry and biophysics.
[378] R. Hardman,et al. Analysis and quantitation of splicing variants of the TPA-inducible PGHS-1 mRNA in rat tracheal epithelial cells. , 1995, Archives of biochemistry and biophysics.
[379] J. Gierse,et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. , 1995, The Biochemical journal.
[380] B. Spiegelman,et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. , 1995, Cell.
[381] K. Seibert,et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[382] S. Iacobelli,et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.
[383] H. Jacobson,et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. , 1994, The Journal of clinical investigation.
[384] H. Chan,et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. , 1994, Biochimica et biophysica acta.
[385] R. Copeland,et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[386] J. Mitchell,et al. Cyclo‐oxygenase and nitric oxide synthase isoforms in rat carrageenin‐induced pleurisy , 1994, British journal of pharmacology.
[387] J. Vane,et al. Induction of cyclo‐oxygenase‐2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone , 1994, British journal of pharmacology.
[388] P. Barnes,et al. Cytokines as mediators of chronic asthma. , 1994, American journal of respiratory and critical care medicine.
[389] M. Percival,et al. High-level expression of active human cyclooxygenase-2 in insect cells. , 1994, Archives of biochemistry and biophysics.
[390] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[391] H. Herschman,et al. v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element , 1994, Molecular and cellular biology.
[392] A. Ristimäki,et al. Structure of the human cyclo-oxygenase-2 gene. , 1994, The Biochemical journal.
[393] S. Srivastava,et al. IL-1 beta stabilizes COX II mRNA in renal mesangial cells: role of 3'-untranslated region. , 1994, The American journal of physiology.
[394] C. Wei,et al. Interaction between nitric oxide and prostaglandin H synthase. , 1994, Archives of biochemistry and biophysics.
[395] N. Hilschmann,et al. Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. , 1994, Biological chemistry Hoppe-Seyler.
[396] S. Rodan,et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. , 1994, The Journal of clinical investigation.
[397] A. Ristimäki,et al. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. , 1994, The Journal of biological chemistry.
[398] E. Remmers,et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. , 1994, The Journal of clinical investigation.
[399] P. Loll,et al. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.
[400] L. Knodel. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs , 1994 .
[401] C. Pawlowski,et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. , 1994, European journal of rheumatology and inflammation.
[402] A. Ristimäki,et al. Cyclooxygenase Gene Expression in Inflammation and Angiogenesis a , 1993, Annals of the New York Academy of Sciences.
[403] J. Richards,et al. Transcriptional regulation of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells. Evidence for the role of a cis-acting C/EBP beta promoter element. , 1993, The Journal of biological chemistry.
[404] W. Xie,et al. Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. , 1993, Archives of biochemistry and biophysics.
[405] F. Laghi Pasini,et al. Inhibition of neutrophil function in vitro by nimesulide. Preliminary evidence of an adenosine-mediated mechanism. , 1993, Arzneimittel-Forschung.
[406] J. Otto,et al. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. , 1993, The Journal of biological chemistry.
[407] Carol A. Barnes,et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids , 1993, Neuron.
[408] A. Kaszniak,et al. Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.
[409] M. Currie,et al. Nitric oxide activates cyclooxygenase enzymes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[410] D. Dewitt,et al. Expression of the murine prostaglandin (PGH) synthase-1 and PGH synthase-2 isozymes in cos-1 cells. , 1993, Journal of lipid mediators.
[411] M. Holtzman,et al. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. , 1992, The Journal of biological chemistry.
[412] T. Hla,et al. Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[413] T. Shimokawa,et al. Prostaglandin endoperoxide synthase. The aspirin acetylation region. , 1992, The Journal of biological chemistry.
[414] V. Winn,et al. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[415] S. Jimenez,et al. Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha. , 1992, The Journal of biological chemistry.
[416] N. Abraham,et al. Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. , 1992, The American journal of physiology.
[417] T. Shimokawa,et al. Expression of prostaglandin endoperoxide synthase-1 in a baculovirus system. , 1992, Biochemical and biophysical research communications.
[418] H. Herschman,et al. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. , 1992, The Journal of biological chemistry.
[419] D. Dewitt,et al. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5'-flanking regulatory sequences. , 1992, Archives of biochemistry and biophysics.
[420] F. Dallegri,et al. Inhibition of the neutrophil oxidative response induced by the oral administration of nimesulide in normal volunteers. , 1992, Journal of clinical & laboratory immunology.
[421] J. Case,et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. , 1992, The Journal of clinical investigation.
[422] P. Leese. Comparison of the effects of etodolac SR and naproxen on gastro-intestinal blood loss. , 1992, Current medical research and opinion.
[423] V. Winn,et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. , 1991, The Journal of biological chemistry.
[424] J. Fries,et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. , 1991, The American journal of medicine.
[425] A. Iggo,et al. Effects of paracetamol and aspirin on neural activity of joint mechanonociceptors in adjuvant arthritis , 1991, British journal of pharmacology.
[426] O. Hayaishi. Molecular mechanisms of sleep‐wake regulation: roles of prostaglandins D2 and E2 , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[427] B. Varnum,et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.
[428] R. Murphy,et al. Structural identification of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells. , 1991, The Journal of biological chemistry.
[429] G. FitzGerald,et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[430] R. Erikson,et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[431] A. Iggo,et al. PGI2-induced activation and sensitization of articular mechanonociceptors , 1991, Neuroscience Letters.
[432] W. Ray,et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. , 1991, Annals of internal medicine.
[433] W. Xie,et al. Multiple Cyclooxygenases: Cloning of a Mitogen-Inducible Form , 1991 .
[434] M. Schattenkirchner. Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. , 1991, Current medical research and opinion.
[435] M. Betz,et al. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. , 1991, Journal of immunology.
[436] T. Onaya,et al. Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neuropathy. , 1991, Prostaglandins.
[437] J. M. Bailey,et al. Prostaglandins, Leukotrienes, Lipoxins, and PAF , 1991, GWUMC Department of Biochemistry Annual Spring Symposia.
[438] T. Shimokawa,et al. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. , 1990, The Journal of biological chemistry.
[439] K. Seibert,et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.
[440] G. Rossoni,et al. Antianaphylactic and antihistaminic activity of the non-steroidal anti-inflammatory compound nimesulide in guinea-pig. , 1990, Arzneimittel-Forschung.
[441] E. Bleecker,et al. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. , 1990, The American review of respiratory disease.
[442] S. Marney,et al. Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effect of indomethacin. , 1990, The American review of respiratory disease.
[443] I. Macara,et al. Persistent induction of cyclooxygenase in p60v-src-transformed 3T3 fibroblasts. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[444] Eveline,et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. , 1990, The Journal of biological chemistry.
[445] J. Filep,et al. Potent thromboxane-mediated in vitro bronchoconstrictor effect of endothelin in the guinea-pig. , 1990, European journal of pharmacology.
[446] S. G. Farmer,et al. Airway epithelium-derived inhibitory factor. , 1990, TIPS - Trends in Pharmacological Sciences.
[447] Bacon Pa. An overview of the efficacy of etodolac in arthritic disorders. , 1990 .
[448] P. Bacon. An overview of the efficacy of etodolac in arthritic disorders. , 1990, European journal of rheumatology and inflammation.
[449] C. Yokoyama,et al. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. , 1989, Biochemical and biophysical research communications.
[450] G. Rosen,et al. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. , 1989, Biochemical and biophysical research communications.
[451] E. Akarsu,et al. Iloprost-induced writhing in mice and its suppression by morphine. , 1989, Methods and findings in experimental and clinical pharmacology.
[452] D. Levy,et al. Identification of a phorbol ester-repressible v-src-inducible gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[453] V. Sukhatme,et al. Nucleotide sequence of a cDNA encoding TIS11, a message induced in Swiss 3T3 cells by the tumor promoter tetradecanoyl phorbol acetate. , 1989, Oncogene.
[454] P. Barnes,et al. Influence of epithelium on guinea pig airway responses to tachykinins: role of endopeptidase and cyclooxygenase. , 1989, The Journal of pharmacology and experimental therapeutics.
[455] B. Weichman,et al. Production of prostacyclin in mice following intraperitoneal injection of acetic acid, phenylbenzoquinone and zymosan: its role in the writhing response. , 1988, Prostaglandins.
[456] R. Kulmacz,et al. Prostaglandin H synthase: distinct binding sites for cyclooxygenase and peroxidase substrates. , 1988, Archives of biochemistry and biophysics.
[457] T. Tanabe,et al. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence , 1988, FEBS letters.
[458] D. Remick,et al. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. , 1988, The Journal of biological chemistry.
[459] M. Wikström. Protonic sidedness of the binuclear iron‐copper centre in cytochrome oxidase , 1988, FEBS letters.
[460] P. Needleman,et al. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). , 1988, The Journal of biological chemistry.
[461] Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[462] P. Keeting,et al. Examination of mouse and rat tissues for evidence of dual forms of the fatty acid cyclooxygenase. , 1988, Biochemical pharmacology.
[463] A. Szczeklik,et al. Aspirin‐induced asthma as a viral disease , 1988, Clinical allergy.
[464] L. Marnett,et al. Controlled tryptic digestion of prostaglandin H synthase. Characterization of protein fragments and enhanced rate of proteolysis of oxidatively inactivated enzyme. , 1987, The Journal of biological chemistry.
[465] T. Kaneko,et al. Postnatal changes in the localization of prostaglandin D synthetase from neurons to oligodendrocytes in the rat brain. , 1987, The Journal of biological chemistry.
[466] G. Kelloff,et al. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. , 1987, Cancer research.
[467] C. Patrono,et al. The clinical significance of inhibition of renal prostaglandin synthesis. , 1987, Kidney international.
[468] J. Coutant,et al. The role of prostaglandins in the nociceptive response induced by intraperitoneal injection of zymosan in mice , 1987, British journal of pharmacology.
[469] M. Sanda,et al. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. , 1987, The Journal of rheumatology.
[470] F. Hirata,et al. Regulation of prostaglandin formation by glucocorticoids and their second messenger, lipocortins. , 1987, Journal of steroid biochemistry.
[471] A. Kumar,et al. Isolation of the cDNA for human prostaglandin H synthase. , 1986, Prostaglandins.
[472] G. Shaw,et al. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation , 1986, Cell.
[473] J. Larrick,et al. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. , 1986, Biochemical and biophysical research communications.
[474] J. Mullane,et al. The Effect of Etodolac Administration on Renal Function in Patients With Arthritis , 1986, Journal of clinical pharmacology.
[475] N. Pawlowski,et al. Compartmentalized regulation of macrophage arachidonic acid metabolism , 1986, The Journal of experimental medicine.
[476] C. Dollery,et al. Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. , 1986, The American review of respiratory disease.
[477] Parker Cw. Leukotrienes and prostaglandins in the immune system. , 1986 .
[478] S. Kunkel,et al. Prostaglandins as endogenous mediators of interleukin 1 production. , 1986, Journal of immunology.
[479] C. W. Parker. Leukotrienes and prostaglandins in the immune system. , 1986, Advances in prostaglandin, thromboxane, and leukotriene research.
[480] P. Needleman,et al. Thromboxane synthase is preferentially conserved in activated mouse peritoneal macrophages. , 1985, The Journal of clinical investigation.
[481] M. Schwartzman,et al. Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase , 1985, Nature.
[482] B. Kommerell,et al. Human platelet-derived growth factor stimulates prostaglandin synthesis by activation and by rapid de novo synthesis of cyclooxygenase. , 1985, The Journal of clinical investigation.
[483] T. Hla,et al. Restoration of prostacyclin synthase in vascular smooth muscle cells after aspirin treatment: regulation by epidermal growth factor. , 1985, Journal of lipid research.
[484] J. Mullane,et al. Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects , 1985 .
[485] P. Needleman,et al. A mononuclear cell factor is a potent agonist of prostaglandin biosynthesis in cultured human fibroblasts and smooth muscle and endothelial cells. , 1985, Advances in prostaglandin, thromboxane, and leukotriene research.
[486] G. Dibona,et al. Interactions among renal nerves, prostaglandins, and renal arterial pressure in the regulation of renin release. , 1984, The American journal of physiology.
[487] S. Holgate,et al. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. , 1984, The New England journal of medicine.
[488] S. Narumiya,et al. Regional Distribution of Prostaglandins D2, E2, and F2α and Related Enzymes in Postmortem Human Brain , 1984, Journal of neurochemistry.
[489] J. Mullane,et al. Gastrointestinal Microbleeding Associated with the Use of Etodolac, Ibuprofen, Indomethacin, and Naproxen in Normal Males , 1984, Journal of clinical pharmacology.
[490] M. Pulkkinen. The effect of nimesulide on intrauterine pressure in dysmenorrhoeic women , 1984 .
[491] T. Miller. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. , 1983, The American journal of physiology.
[492] H. Thaler,et al. Prostaglandins in breast cancer: relationship to disease stage and hormone status. , 1983, British Journal of Cancer.
[493] G. Roth,et al. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. , 1983, Biochemistry.
[494] C. W. Parker,et al. Metabolites of arachidonic acid , 1983, Clinical reviews in allergy.
[495] G. FitzGerald,et al. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. , 1983, Circulation.
[496] J. Mehta,et al. Comparison of umbilical vein models for measurement of relative prostacyclin and thromboxane production. , 1982, Prostaglandins.
[497] O. Hayaishi,et al. Prostaglandin D2 induces sleep when microinjected into the preoptic area of conscious rats. , 1982, Biochemical and biophysical research communications.
[498] O. Hayaishi,et al. An NADP-linked 15-hydroxyprostaglandin dehydrogenase specific for prostaglandin D2 from swine brain. , 1982, The Journal of biological chemistry.
[499] K. Nakao,et al. Prostaglandin D2 in rat brain, spinal cord and pituitary: basal level and regional distribution. , 1982, Life sciences.
[500] S. Narumiya,et al. Role of prostaglandin D2 in the hypothermia of rats caused by bacterial lipopolysaccharide. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[501] P. Gullino,et al. Role of prostaglandin E1 and copper in angiogenesis. , 1982, Journal of the National Cancer Institute.
[502] F. ten Hoor,et al. Prostacyclin production of the isolated pulsatingly perfused rat aorta. , 1982, Journal of pharmacological methods.
[503] L. Turnberg,et al. Demonstration of a pH gradient across the mucus layer on the surface of human gastric mucosa in vitro. , 1982, Gut.
[504] W. Lands,et al. Effects of non-steroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities. , 1982, Prostaglandins.
[505] P. Needleman,et al. Evidence for Two Distinct Forms of Fatty Acid Cyclooxygenase in Brain , 1982, Journal of neurochemistry.
[506] Robert A. Lewis,et al. Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds , 1981, Nature.
[507] G. Pasero,et al. THE SYNOVIAL PROSTAGLANDIN SYSTEM IN CHRONIC INFLAMMATORY ARTHRITIS: DIFFERENTIAL EFFECTS OF STEROIDAL AND NONSTEROIDAL ANTI‐INFLAMMATORY DRUGS , 1981, British journal of pharmacology.
[508] Morris Pollard,et al. Treatment of Chemically-Induced Intestinal Cancers with Indomethacin 1 , 1981, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[509] L. Levine. Arachidonic acid transformation and tumor production. , 1981, Advances in cancer research.
[510] A. Marcus,et al. Arachidonic acid metabolism in platelets and endothelial cells. , 1981, Progress in lipid research.
[511] J. Oates,et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. , 1980, The New England journal of medicine.
[512] Murota Seiitsu,et al. Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells , 1980 .
[513] D. Gordon,et al. Is prostacyclin in the major pro-inflammatory prostanoid in joint fluid? , 1980, Life sciences.
[514] M. Buytenhek,et al. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. , 1980, European journal of biochemistry.
[515] K. Watanabe,et al. An NADP-linked prostaglandin D dehydrogenase in swine brain. , 1980, The Journal of biological chemistry.
[516] A. Allen,et al. Mucus and bicarbonate secretion in the stomach and their possible role in mucosal protection. , 1980, Gut.
[517] J. Ozols,et al. Structural characteristics of prostaglandin synthetase from sheep vesicular gland. , 1980, The Journal of biological chemistry.
[518] S. Murota,et al. Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells. , 1980, Biochimica et biophysica acta.
[519] G. Reid,et al. The purification of a respiratory oxidase complex from escherichia coli , 1980, FEBS letters.
[520] R. Tompkins. Nonsteroidal anti-inflammatory drugs. , 2019, Minnesota medicine.
[521] A. Robert,et al. Cytoprotection by Prostaglandins in Rats Prevention of Gastric Necrosis Produced by Alcohol, HCl, NaOH, Hypertonic NaCl, and Thermal Injury , 1979 .
[522] C. Johansson,et al. Stimulation by intragastrically administered E2 prostaglandins of human gastric mucus output , 1979, European journal of clinical investigation.
[523] E. Jaffe,et al. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. , 1979, The Journal of clinical investigation.
[524] S. Yamamoto,et al. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. , 1979, The Journal of biological chemistry.
[525] R. Branch,et al. Effect of PGI2, PGE2 and 6-keto PGF1α on canine gastric blood flow and acid secretion , 1978 .
[526] J. Vane,et al. Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGF1α in the rat paw , 1978 .
[527] S. Yamamoto,et al. Prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. Inactivation and activation by heme and other metalloporphyrins. , 1978, The Journal of biological chemistry.
[528] S. Ferreira,et al. The hyperalgesic effects of prostacyclin and prostaglandin E2. , 1978, Prostaglandins.
[529] J. Vane,et al. Actions of prostacyclin (PGI2) and its product, 6-oxo-PGF1alpha on the rat gastric mucosa in vivo and in vitro. , 1978, Prostaglandins.
[530] M. Peck,et al. Role of prostaglandin-mediated vasodilatation in inflammation , 1977, Nature.
[531] R. Zusman,et al. Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture. Stimulation by angiotensin II, bradykinin, and arginine vasopressin. , 1977, The Journal of clinical investigation.
[532] T. Żebro,et al. Prostaglandins from tumours of human large bowel. , 1977, British Journal of Cancer.
[533] M. Buytenhek,et al. Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. , 1977, Biochimica et biophysica acta.
[534] T. Shen. Prostaglandin Synthetase Inhibitors I , 1977 .
[535] W. Lands,et al. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. , 1976, The Journal of biological chemistry.
[536] N. Silverman,et al. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. , 1976, The New England journal of medicine.
[537] J. Vane,et al. Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. , 1976, Prostaglandins.
[538] M. Hamberg,et al. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides , 1976, Nature.
[539] S. Yamamoto,et al. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. , 1976, The Journal of biological chemistry.
[540] Megan E. Pahmier,et al. Double Blind , 2001, International Psychogeriatrics.
[541] A. Szczeklik,et al. PROSTAGLANDINS AND ASPIRIN-INDUCED ASTHMA , 1976, The Lancet.
[542] G J Roth,et al. Acetylation of prostaglandin synthase by aspirin. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[543] Allan H. Smith,et al. Subversion of immune system by tumor cells and role of prostaglandins. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[544] M. Hamberg,et al. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[545] M. Hamberg,et al. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[546] J. Vane,et al. Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol) , 1972, Nature.
[547] S. Ferreira. Prostaglandins, aspirin-like drugs and analgesia. , 1972, Nature: New biology.
[548] M. Sugawara. The National Research Centre for Disaster Prevention , 1972, Nature.
[549] W. Lands,et al. Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland. , 1972, Biochemistry.
[550] S. Wendlandt,et al. Effects on body temperature of prostaglandins of the A, E and F series on injection into the third ventricle of unanaesthetized cats and rabbits , 1971, The Journal of physiology.
[551] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[552] L. Solomon,et al. Prostaglandin on cutaneous vasculature. , 1968, The Journal of investigative dermatology.
[553] P. Sherlock,et al. Progress in gastroenterology , 1968 .
[554] A. Robert,et al. Inhibition of gastric secretion by prostaglandins , 1967, The American journal of digestive diseases.
[555] L. Michotte,et al. [CLINICAL TRIAL OF INDOMETHACIN]. , 1964, Rhumatologie.
[556] D. Nugteren,et al. Enzymatic Conversion of All-cis-Polyunsaturated Fatty Acids into Prostaglandins , 1964, Nature.
[557] B. Samuelsson,et al. THE ENZYMATIC FORMATION OF PROSTAGLANDIN E2 FROM ARACHIDONIC ACID PROSTAGLANDINS AND RELATED FACTORS 32. , 1964, Biochimica et biophysica acta.
[558] B. Samuelsson. ISOLATION AND IDENTIFICATION OF PROSTAGLANDINS FROM HUMAN SEMINAL PLASMA. 18. PROSTAGLANDINS AND RELATED FACTORS. , 1963, The Journal of biological chemistry.
[559] F. Plum. Handbook of Physiology. , 1960 .
[560] Ebenezer Howard,et al. Welwyn Garden City , 1930 .